Formación Académica y Profesional
Licenciado Matemáticas (Especialidad Fundamentales) por UCM, MBA Executive, MBA Financial Markets, Project Management Excellence Certified
Financial Markets Services Consulting, IT CIO ACO Grupo Santander, IBM Global Services Principal, Electronic Data System Client Ececutive

Welcome

The mathematician of the Complutense University of Madrid, José-Vidal Ruiz Varela, argues that Europe must raise its borrowing limit, leaving its deflationary policy. Meanwhile, USA must correct debt and raise the interest rates. Raising the interest rates in the USA and dropping them in Europe, recovers the European domestic demand and EE.UU may return to invest in Europe, with a stronger dollar, without any problem, generating hundreds of thousands of Jobs

Curso Superior de #AnálisisDeDatos Contacto : admin@fasesdelabolsa.net

Curso Superior de #AnálisisDeDatos Contacto : admin@fasesdelabolsa.net
40 horas. Profesor : José - Vidal Ruiz Varela

Clases Particulares para hacer crecer tu Negocio. #Bigdata #DesarrolloCognitivo

Clases Particulares para hacer crecer tu Negocio. #Bigdata #DesarrolloCognitivo
Profesor : José - Vidal Ruiz Varela

#Bigdata y #Desarrollo #Cognitivo para Personas entre 15 y 65 años

#Bigdata y #Desarrollo #Cognitivo para Personas entre 15 y 65 años
Profesor : José - Vidal Ruiz Varela

Agenda Macro

Agenda de Economía y Finanzas en el Calendario Económico de Investing.com Español.

PULSO DE MERCADOS

Principales Materias Primas


Commodities entregados por Forexpros.es

Cotización de las Principales divisas en tiempo real

Cotización de las Principales divisas en tiempo real
e-mail : admin@fasesdelabolsa.net

Principales Índices Mundiales


El IBEX 35 y los Índices del Mundo son proveídos por Investing.com Español.

Merck reports second-quarter drop in profit, sales

NEW YORK (MarketWatch)
Merck & Co. Inc. reported its second-quarter profit fell to $906 million, or 30 cents a share, from $1.79 billion, or 58 cents a share, a year earlier
Adjusted to exclude acquisition and restructuring costs, the company reported profit of $2.53 billion, or 84 cents a share, down from $3.23 billion, or $1.05 a share, a year ago
Revenue fell to $11.01 billion, from $12.31 billion a year earlier, the pharmaceuticals company said
Analysts had expected earnings of 82 cents a share on revenue of $11.24 billion, according to FactSet
Sales of Singulair, the company's asthma and allergy drug, were down 80%, Merck said
The company reiterated its full-year 2013 earnings-per-share target of $1.84 to $2.05, and its adjusted target of $3.45 to $3.55
Publicar un comentario